Finanzen von Dare Bioscience Inc (DARE)DAREDare Bioscience Inc

Evaluating the bottom line, Dare Bioscience Inc maintains a gross margin of -70.57%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1582.53%, while the net margin is -1590.42%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively DARE converts its operational activities into shareholder value.

In the context of the broader market, DARE competes directly with industry leaders such as ADIL and LSTA. With a market capitalization of $14.22M, it holds a significant position in the sector. When comparing efficiency, DARE's gross margin of -70.57% stands against ADIL's N/A and LSTA's N/A. Such benchmarking helps identify whether Dare Bioscience Inc is trading at a premium or discount relative to its financial performance.

DARE has shown a troubling financial performance with a net income loss of -$2,982,773 in Q2 2026 and a forward P/E ratio of 1.27, indicating potential undervaluation but also reflecting ongoing losses.